Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours - UPT - unfit

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001959-38-DK

Enrollment

Registered

2005-06-16

Start date

2005-07-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75

Interventions

Trade Name: Gemzar Product Name: Gemzar Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Gemcitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unknown primary tumour Performance 2 or age 66 to 75 Measurable lesion by RECIST Expected life time more than 12 weeks Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Performance 0 or 1 and age below 66 neuropathy another known cancer disease

Design outcomes

Primary

Measure	Time frame
Main Objective: response rate ;Secondary Objective: side effects time to progression;Primary end point(s): response rate	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026